A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company

RARECast - A podcast by RARECast - Thursdays

Categories:

Business

Stan Abel, CEO of ProJenX, about ALS, the company’s lead therapeutic candidate prosetin, and the company’s ongoing relationship with Project ALS and Columbia University.